Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00284531 · ClinicalTrials.gov registry record · Phase 1
Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients
A Phase 1 study, sponsored by Baylor College of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00284531 is a Phase 1 study that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 1 participants.
The verdict
NCT00284531, a Phase 1 study, was terminated before completion, sponsored by Baylor College of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This protocol is designed to obtain information on the drug levels, metabolism, and safety of daclizumab (Zenapax(R)) in children and adolescents undergoing cardiac transplantation. In addition to the drug safety and metabolism information, the number and severity of rejection episodes in patients undergoing cardiac transplantation using the standard immunosuppressive drugs plus daclizumab will be compared with patients who have previously undergone cardiac transplantation at the Baylor College of Medicine and received the same standard immunosuppressive drugs without daclizumab.
Interventions
- DRUG Daclizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00284531
The ClinicalTrials.gov registry entry for NCT00284531 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daclizumab is the first listed.
NCT00284531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00284531 about?
NCT00284531 is a clinical study titled "Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients". This protocol is designed to obtain information on the drug levels, metabolism, and safety of daclizumab (Zenapax(R)) in children and adolescents undergoing cardiac transplantation. In addition to the drug safety and metabolism information, the number and severity of rejection episodes in patients u...
What is the current status of trial NCT00284531?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2003-10. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00284531?
The interventions under investigation include: Daclizumab (DRUG).
Who is sponsoring clinical trial NCT00284531?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.